Amyloid activates GSK-3beta to aggravate neuronal tauopathy in bigenic mice.
(2008) The American Journal of Pathology : cellular and molecular biology of disease — Vol. 172, n° 3, p. 786-798 (2008)
Files
AmyloidactivatesGSK3beta.pdf
Open Access - Adobe PDF
- 2.45 MB
Details
- Authors
- Abstract
- The hypothesis that amyloid pathology precedes and induces the tau pathology of Alzheimer's disease is experimentally supported here through the identification of GSK-3 isozymes as a major link in the signaling pathway from amyloid to tau pathology. This study compares two novel bigenic mouse models: APP-V717I x Tau-P301L mice with combined amyloid and tau pathology and GSK-3beta x Tau-P301L mice with tauopathy only. Extensive and remarkable parallels were observed between these strains including 1) aggravation of tauopathy with highly fibrillar tangles in the hippocampus and cortex; 2) prolonged survival correlated to alleviated brainstem tauopathy; 3) development of severe cognitive and behavioral defects in young adults before the onset of amyloid deposition or tauopathy; and 4) presence of pathological phospho-epitopes of tau, including the characteristic GSK-3beta motif at S396/S404. Both GSK-3 isozymes were activated in the brain of parental APP-V717I amyloid mice, even at a young age when cognitive and behavioral defects are evident but before amyloid deposition. The data indicate that amyloid induces tauopathy through activation of GSK-3 and suggest a role for the kinase in maintaining the functional integrity of adult neurons.
- Affiliations
Citations
Terwel, D., Muyllaert, D., Dewachter, I., Borghgraef, P., Croes, S., Devijver, H., & Van Leuven, F. (2008). Amyloid activates GSK-3beta to aggravate neuronal tauopathy in bigenic mice. The American Journal of Pathology : cellular and molecular biology of disease, 172(3), 786-798. https://doi.org/10.2353/ajpath.2008.070904 (Original work published 2008)